• PharmAla Biotech (MDMA) and its manufacturing partners have received an export permit for 300 grams of its LaNeo MDMA
  • PharmAla believes this is the largest single Health Canada export permit ever granted
  • Nicholas Kadysh, CEO of PharmAla, met with Sabrina Cuthbert to discuss the news
  • PharmAla (MDMA) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA
  • Pharmala Biotech Holdings Inc. (MDMA) opened trading at C$0.045

PharmAla Biotech (MDMA) and its manufacturing partners have received an export permit for 300 grams of its LaNeo MDMA.

PharmAla believes this is the largest single Health Canada export permit ever granted by weight to date.

Nicholas Kadysh, CEO of PharmAla, met with Sabrina Cuthbert to discuss the news.

“We’re incredibly proud of this milestone. It is additional proof that the clinical development of MDMA is moving forward. PharmAla exists to assist our client researchers around the world by not only saying we’ll provide them with research materials but actually delivering. The global psychedelics industry is still in its infancy, but strong demand for these molecules helps ensure a foundational role for manufacturers like PharmAla.”

PharmAla (MDMA) is a biotechnology company focused on the research, development, and manufacturing of MDXX-class molecules, including MDMA.

Pharmala Biotech Holdings Inc. (MDMA) opened trading at C$0.045.


More From The Market Online

Buzz on the Bullboards: From innovating traffic enforcement to cancer breakthroughs

The past week on the TSX has been one for the books, with significant gains driven largely by advancements in the technology sector.

Sparta and Parametric join forces to advance autonomous medicine project

Sparta Group (TSX.V:SAY) signed a strategic partnership with Parametric Design Canada Inc., a leader in augmented reality (AR) technologies.

MediPharm bolsters revenue with new medical cannabis products

MediPharm Labs (TSX:LABS), a cannabis pharmaceutical stock, increases revenue through a new licensing agreement with Remidose Aerosols.
clinical trial

Sona Nanotech’s therapy shines in cancer trials

Sona Nanotech (CSE:SONA) revels that its targeted hyperthermia therapy has shown positive results in a second preclinical cancer model.